Liaoning Chengda Biotechnology Co., Ltd. (SHA:688739)
China · Delayed Price · Currency is CNY 19.85
-0.48 (-2.36%)
At close: Sep 11, 2026
SHA:688739 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8,163 | 10,594 | 10,612 | 13,539 | 12,668 | 31,704 | |
Market Cap Growth | -27.70% | -0.17% | -21.62% | 6.87% | -60.04% | - |
Enterprise Value | 3,048 | 5,536 | 5,273 | 7,974 | 7,019 | 29,988 |
Last Close Price | 19.85 | 25.64 | 24.89 | 30.42 | 27.64 | 67.80 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 193.05 | 80.38 | 30.96 | 29.06 | 17.74 | 35.52 |
Forward PE | 44.11 | 23.69 | 23.60 | 18.60 | - | - |
PS Ratio | 6.00 | 7.62 | 6.33 | 7.74 | 6.98 | 15.18 |
PB Ratio | 0.87 | 1.13 | 1.11 | 1.41 | 1.31 | 3.39 |
P/TBV Ratio | 0.96 | 1.16 | 1.13 | 1.44 | 1.34 | 3.44 |
P/FCF Ratio | 113.70 | 323.16 | 76.63 | 108.30 | 363.13 | - |
P/OCF Ratio | 28.63 | 31.08 | 21.18 | 20.00 | 23.18 | 62.61 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.24 | 3.98 | 3.15 | 4.56 | 3.87 | 14.36 |
EV/EBITDA Ratio | 14.22 | 24.34 | 9.55 | 12.76 | 8.24 | 27.24 |
EV/EBIT Ratio | - | 96.51 | 13.70 | 15.80 | 9.55 | 30.29 |
EV/FCF Ratio | 42.45 | 168.87 | 38.08 | 63.79 | 201.20 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 |
Debt / FCF Ratio | 0.10 | 0.29 | 0.11 | 0.16 | 0.63 | - |
Net Debt / Equity Ratio | -0.55 | -0.56 | -0.57 | -0.59 | -0.63 | -0.68 |
Net Debt / EBITDA Ratio | -24.68 | -22.89 | -9.93 | -9.09 | -7.12 | -5.80 |
Net Debt / FCF Ratio | -71.28 | -158.80 | -39.61 | -45.45 | -173.88 | 3244.02 |
Asset Turnover | 0.14 | 0.14 | 0.17 | 0.17 | 0.18 | 0.29 |
Inventory Turnover | 0.94 | 0.87 | 0.72 | 0.76 | 0.56 | 0.66 |
Quick Ratio | 22.77 | 20.84 | 16.73 | 19.05 | 26.38 | 25.52 |
Current Ratio | 24.57 | 22.58 | 18.01 | 20.32 | 28.23 | 26.98 |
Return on Equity (ROE) | 0.46% | 1.39% | 3.58% | 4.84% | 7.51% | 13.25% |
Return on Assets (ROA) | -0.01% | 0.36% | 2.39% | 3.13% | 4.63% | 8.67% |
Return on Invested Capital (ROIC) | -0.01% | 1.08% | 8.19% | 10.88% | 19.14% | 34.97% |
Return on Capital Employed (ROCE) | 0.00% | 0.60% | 4.00% | 5.20% | 7.50% | 10.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.52% | 1.24% | 3.23% | 3.44% | 5.64% | 2.81% |
FCF Yield | 0.88% | 0.31% | 1.31% | 0.92% | 0.27% | -0.01% |
Dividend Yield | 0.49% | 0.39% | 3.21% | 2.63% | 3.62% | 1.47% |
Payout Ratio | 96.20% | 249.82% | 96.08% | 89.35% | 58.30% | - |
Buyback Yield / Dilution | -1.69% | 0.29% | 0.71% | 0.37% | -9.48% | -1.77% |
Total Shareholder Return | -1.20% | 0.68% | 3.93% | 3.00% | -5.86% | -0.29% |